Status:
UNKNOWN
Fecal Calprotectin as a Marker for Macroscopic Recurrence of Crohn's Disease After Intestinal Resection
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Complicated Crohn's Disease
Eligibility:
All Genders
18+ years
Brief Summary
our primary objective is to correlate fecal calprotectin with currently used Crohn's disease endoscopic disease activity scores used for predicting endoscopic recurrence. Our secondary objectives will...
Detailed Description
Fecal calprotectin is a non invasive marker of intestinal inflammation. It is highly sensitive for the detection of active Crohn's disease (13) and mucosal healing (14). Levels higher than 250 mg/L ar...
Eligibility Criteria
Inclusion
- at least 18 years of age
- confirmed Crohn's disease
- undergoing intestinal resection for complicated Crohn's disease
Exclusion
- Ileostomy
- pregnancy
- stricturoplasty without resection
- patients with diffuse active disease at other sites
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00922415
Start Date
August 1 2009
End Date
December 1 2011
Last Update
December 16 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dep. of Gastroenterology, Tel Aviv medical center
Tel Aviv, Israel